Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2007 Aug 24;9(4):336–341. doi: 10.1007/s11926-007-0053-7

Kawasaki disease: 40 years after the original report

Abraham Gedalia 1,✉
PMCID: PMC7089469  PMID: 17688844

Abstract

The cause of Kawasaki disease (KD) remains unknown, although a number of epidemiologic and clinical observations suggest it is triggered by one or more infectious agents, each of which can result in the clinical manifestation of the disease. Advances have been made in the management of the disease with the introduction of aspirin and intravenous immunoglobulin (IVIG), which have had a significant impact on lowering the rate of coronary artery aneurysms and death from the disease. Questions remain regarding the management of those patients who fail to respond to IVIG. It appears that some patients with severe KD who are resistant to IVIG may benefit from IV pulse steroid therapy or infliximab infusion. However, a recent multicenter, randomized, controlled trial did not support the addition of a pulsed dose of intravenous methylprednisolone to the conventional IVIG therapy for the primary treatment of KD. It remains to be seen whether other anti-inflammatory agents such as immunosuppressive therapies or new biologics will play a role in the management of patients with KD.

Keywords: Rheumatic Fever, Coronary Aneurysm, Kawasaki Syndrome, Severe Kawasaki Disease, Febrile Mucocutaneous Lymph Node Syndrome

References and Recommended Reading

  • 1.Taubert K.A., Rowley A.H., Shulman S.T. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991;119:279–282. doi: 10.1016/S0022-3476(05)80742-5. [DOI] [PubMed] [Google Scholar]
  • 2.Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes [in Japanese] Arerugi. 1967;16:178–222. [PubMed] [Google Scholar]
  • 3.Yanagawa H., Nakamura Y., Ojima T., et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J. 1999;18:64–66. doi: 10.1097/00006454-199901000-00015. [DOI] [PubMed] [Google Scholar]
  • 4.Holman R.C., Belay E.D., Clarke M.J., et al. Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J. 1999;18:451–455. doi: 10.1097/00006454-199905000-00010. [DOI] [PubMed] [Google Scholar]
  • 5.Holman R.C., Curns A.T., Belay E.D., et al. Kawasaki syndrome hospitalizations in the United States. Pediatrics. 2003;112:495–501. doi: 10.1542/peds.112.3.495. [DOI] [PubMed] [Google Scholar]
  • 6.Mason W.H., Takahashi M. Kawasaki syndrome. Clin Infect Dis. 1999;28:169–185. doi: 10.1086/515133. [DOI] [PubMed] [Google Scholar]
  • 7.Yanagawa H., Yashiro M., Nakamura Y., et al. Nationwide surveillance of Kawasaki disease in Japan. Pediatr Infect Dis J. 1995;14:69–71. doi: 10.1097/00006454-199501000-00017. [DOI] [PubMed] [Google Scholar]
  • 8.Cohen B.J. Human parvovirus B19 infection in Kawasaki disease [letter] Lancet. 1994;344:59. doi: 10.1016/S0140-6736(94)91081-2. [DOI] [PubMed] [Google Scholar]
  • 9.Marchette N.J., Melish M.E., Hicks R., et al. Epstein-Barr virus and other herpes infections in Kawasaki syndrome. J Infect Dis. 1990;161:680–684. doi: 10.1093/infdis/161.4.680. [DOI] [PubMed] [Google Scholar]
  • 10.Dominguez S.R., Anderson M.S., Glodé M.P., et al. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki disease. J Infect Dis. 2006;194:1697–1701. doi: 10.1086/509509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dajani A.S., Taubert K.A., Gerber M.A., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776–1780. doi: 10.1161/01.cir.87.5.1776. [DOI] [PubMed] [Google Scholar]
  • 12.Abinum M., Cant A.J. Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome [letter] Lancet. 1994;343:300. doi: 10.1016/S0140-6736(94)91150-9. [DOI] [PubMed] [Google Scholar]
  • 13.Davis H.D., Kirk V., Jadavji T., et al. Simultaneous presentation of Kawasaki disease and toxic syndrome in an adolescent male. Pediatr Infect Dis J. 1996;15:1136–1137. doi: 10.1097/00006454-199612000-00021. [DOI] [PubMed] [Google Scholar]
  • 14.Meissner H.C., Leung D.Y. Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatric Infect Dis J. 2000;19:91–94. doi: 10.1097/00006454-200002000-00001. [DOI] [PubMed] [Google Scholar]
  • 15.Leung D.Y., Meissner H.C., Fulton D.R., et al. Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome. Lancet. 1993;342:1385–1387. doi: 10.1016/0140-6736(93)92752-F. [DOI] [PubMed] [Google Scholar]
  • 16.Terai M., Miwa K., Williams T., et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis. 1995;172:558–561. doi: 10.1093/infdis/172.2.558. [DOI] [PubMed] [Google Scholar]
  • 17.Rowley A.H., Shulman S.T. New developments in the search for etiologic agent of Kawasaki disease. Curr Opin Pediatr. 2007;19:71–74. doi: 10.1097/MOP.0b013e328012720f. [DOI] [PubMed] [Google Scholar]
  • 18.Dajani A.S., Taubert K.A., Gerber M.A., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776–1780. doi: 10.1161/01.cir.87.5.1776. [DOI] [PubMed] [Google Scholar]
  • 19.Takahashi K., Oharaseki T., Naoe S., et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005;47:305–310. doi: 10.1111/j.1442-200x.2005.02049.x. [DOI] [PubMed] [Google Scholar]
  • 20.Rowley A.H., Shulman S.T., Spike B.T., et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol. 2001;166:1334–1343. doi: 10.4049/jimmunol.166.2.1334. [DOI] [PubMed] [Google Scholar]
  • 21.Brown T.J., Crawford S.E., Cornwall M.L., et al. CD8 T lymphocytes and macrophages infiltrate coronary arteryaneurysm in acute Kawasaki disease. J Infect Dis. 2001;184:940–943. doi: 10.1086/323155. [DOI] [PubMed] [Google Scholar]
  • 22.Gavin P.J., Crawford S.E., Shulman S.T., et al. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol. 2003;23:576–581. doi: 10.1161/01.ATV.0000065385.47152.FD. [DOI] [PubMed] [Google Scholar]
  • 23.Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006;91:847–851. doi: 10.1136/adc.2005.087437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Suzuki A., Miyagawa-Tomota S., Komatsu K., et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int. 2004;46:590–596. doi: 10.1111/j.1442-200x.2004.01943.x. [DOI] [PubMed] [Google Scholar]
  • 25.Kawasaki T., Kosaki T., Okawa S., et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–276. [PubMed] [Google Scholar]
  • 26.Morens D., O’Brien R. Kawasaki disease in the United States. J Infect Dis. 1978;137:91–93. [PubMed] [Google Scholar]
  • 27.Newburger J.W., Takahashi M., Gerber M.A., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–1733. doi: 10.1542/peds.2004-2182. [DOI] [PubMed] [Google Scholar]
  • 28.Freeman A.F., Shulman S.T. Kawasaki disease: Summary of the American Heart Association Guidelines. Am Fam Physicians. 2006;74:1141–1148. [PubMed] [Google Scholar]
  • 29.Beiser A.S., Takahasha M., Baker A.L., et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol. 1998;81:1116–1120. doi: 10.1016/S0002-9149(98)00116-7. [DOI] [PubMed] [Google Scholar]
  • 30.Harada K. Indication for intravenous gammaglobulin treatment for Kawasaki disease. In: Takahasha M., Taubert K., editors. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas, TX: American Heart Association; 1993. pp. 459–462. [Google Scholar]
  • 31.Mori M., Imagawa T., Yasui K., et al. Predictors of coronary artery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr. 2000;137:177–180. doi: 10.1067/mpd.2000.107890. [DOI] [PubMed] [Google Scholar]
  • 32.Nakamura Y., Yashiro M., Uehara R., et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int. 2004;46:33–38. doi: 10.1111/j.1442-200X.2004.01840.x. [DOI] [PubMed] [Google Scholar]
  • 33.Fukunishi M., Kikkawa M., Hamana K., et al. Prediction of non-responsiveness to intravenous high dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000;137:172–176. doi: 10.1067/mpd.2000.104815. [DOI] [PubMed] [Google Scholar]
  • 34.Abuhammour W.M., Hasan R.A., Eljamal A., Asmar B. Kawasaki disease hospitalizations in a predominantly African-American population. Clin Pediatr. 2005;44:721–725. doi: 10.1177/000992280504400812. [DOI] [PubMed] [Google Scholar]
  • 35.Porcalla A.R., Sable C.A., Patel K.M., et al. The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms? Pediatr Cardiol. 2005;26:775–781. doi: 10.1007/s00246-005-0916-5. [DOI] [PubMed] [Google Scholar]
  • 36.Marquez J, Gedalia O, Candia L, et al.: Kawasaki disease: Clinical spectrum of 88 patients in a high prevalence African American population. J Natl Med Assoc 2007, in press. [DOI] [PubMed]
  • 37.Newburger J.W., Takahashi M., Beiser A.S., et al. A single intravenous in fusion of gammaglobulin as compared with four infusions in treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–1639. doi: 10.1056/NEJM199106063242305. [DOI] [PubMed] [Google Scholar]
  • 38.Sundel R.P., Burns J.C., Baker A., Beiser A. Gamma globulin retreatment in Kawasaki disease. J Pediatr. 1993;123:657–659. doi: 10.1016/S0022-3476(05)80972-2. [DOI] [PubMed] [Google Scholar]
  • 39.Wright D.A., Newburger J.W., Baker A., Sundel R.P. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146–149. doi: 10.1016/S0022-3476(96)70447-X. [DOI] [PubMed] [Google Scholar]
  • 40.Kato H., Koike S., Yokoyama T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics. 1979;3:175–179. [PubMed] [Google Scholar]
  • 41.Kijima Y., Kamiya T., Suzuki A., et al. A trial procedure to prevent aneurysm formation of the coronary artery by steroid pulse therapy in Kawasaki disease. Jap Circ J. 1982;46:1239–1242. doi: 10.1253/jcj.46.1239. [DOI] [PubMed] [Google Scholar]
  • 42.Nonaka Z., Maekawa K., Okabe T., et al. Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In: Kato H., et al., editors. Kawasaki disease. Proceedings of the 5th International Kawasaki disease Symposium. Amsterdam: Elsevier Science BV; 1995. pp. 328–331. [Google Scholar]
  • 43.Shinohara M., Sone K., Tomomasa T., Morikawa A. Corticosteroids in the treatment of acute phase of Kawasaki disease. J Pediatr. 1999;135:465–469. doi: 10.1016/S0022-3476(99)70169-1. [DOI] [PubMed] [Google Scholar]
  • 44.Sundel R.P., Baker A.L., Fulton D.R., Newburger J.W. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142:611–616. doi: 10.1067/mpd.2003.191. [DOI] [PubMed] [Google Scholar]
  • 45.Inoue Y., Okada Y., Shinohara M., et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336–341. doi: 10.1016/j.jpeds.2006.05.025. [DOI] [PubMed] [Google Scholar]
  • 46.Newburger J.W., Sleeper L.A., McCrindle B.W., et al. Randomized trial of pulsed corticosteroids therapy for primary for treatment of Kawasaki disease. N Engl J Med. 2007;356:663–675. doi: 10.1056/NEJMoa061235. [DOI] [PubMed] [Google Scholar]
  • 47.Petty R.E., Cassidy J.T. Kawasaki disease. In: Cassidy J.T., Petty R.E., editors. Textbook of Pediatric Rheumatology. 4. Oxford: W.B. Saunders Company; 2001. pp. 580–594. [Google Scholar]
  • 48.Weiss J.E., Eberhard B.A., Chowdhury D., Gotrlieb B.S. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31:808–810. [PubMed] [Google Scholar]
  • 49.Burns J.C., Mason W.H., Hauger S.B., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662–667. doi: 10.1016/j.jpeds.2004.12.022. [DOI] [PubMed] [Google Scholar]
  • 50.Kavey R.E., Allada V., Daniels S.R., et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114:2710–2738. doi: 10.1161/CIRCULATIONAHA.106.179568. [DOI] [PubMed] [Google Scholar]

Articles from Current Rheumatology Reports are provided here courtesy of Nature Publishing Group

RESOURCES